National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ponatinib (Iclusig®) Is indicated for patients in chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation and for Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) patients who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.

 Rapid Review

Commenced Completed Outcome
02/10/2013 01/12/2013 Full HTA Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
01/07/2015  05/01/2016 Reimbursement Not Recommended

Summary